NEDA-3 achievement in early highly active relapsing remitting multiple sclerosis patients treated with Ocrelizumab or Natalizumab

Elisabetta Signoriello, Alessio Signori, Giacomo Lus, Giuseppe Romano, Girolama Alessandra Marfia, Doriana Landi, Francesca Napoli, Emanuele D' Amico, Aurora Zanghí, Paola Sofia Di Filippo, Daniele Caliendo, Antonio Carotenuto, Antonio Luca Spiezia, Roberta Fantozzi, Diego Centonze, Matteo Lucchini, Massimiliano Mirabella, Eleonora Cocco, Jessica Frau, Giorgia Teresa ManiscalcoMaria Elena Di Battista, Matteo Foschi, Andrea Surcinelli, Simona Bonavita, Gianmarco Abbadessa, Livia Pasquali, Maria Di Gregorio, Maria Teresa Ferrò, Maria Pia Sormani, Irene Schiavetti

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)N/A-N/A
JournalMultiple Sclerosis and Related Disorders
Volume87
DOIs
Publication statusPublished - 2024

Keywords

  • High-efficacy disease-modifying therapy (HE DMTs)
  • Highly active MS patients (HAMS)
  • Multiple sclerosis
  • NEDA-3
  • Natalizumab
  • Ocrelizumab

Cite this